Also known as Nubeqa.
Interim Phase III DASL-HiCaP results show darolutamide added to ADT and radiation significantly improves metastasis-free survival versus placebo in high‑risk patients.
Real-world study shows ERLEADA® offers significant survival benefits for mCSPC patients without docetaxel, supporting its use as a standard treatment.
EU approves darolutamide with ADT for mHSPC, based on ARANOTE trial. Offers treatment flexibility with or without chemotherapy, enhancing patient care.
